Pharmacogenomics in the age of personalized medicine

Drug Discovery Today: Technologies

Volumn 21-22, Issue , 2016, Pages 11-16

  Dickmann, Leslie J ^a   Ware, Joseph A ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

AGE RELATED MACULAR DEGENERATION; CLINICAL OUTCOME; COST BENEFIT ANALYSIS; DRUG DEVELOPMENT; DRUG LABELING; DRUG MECHANISM; DRUG SAFETY; GENETIC ANALYSIS; HEALTH CARE PERSONNEL; HEALTH EDUCATION; HUMAN; MULTICENTER STUDY (TOPIC); PERSONALIZED MEDICINE; PHARMACOGENOMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; GENETICS; NEOPLASMS; PHARMACOGENETICS;

DRUG DISCOVERY; DRUG LABELING; HUMANS; NEOPLASMS; PHARMACOGENETICS; PRECISION MEDICINE;

EID: 85004073450     PISSN: None     EISSN: 17406749     Source Type: Journal    
DOI: 10.1016/j.ddtec.2016.11.003     Document Type: Review

References (32)

1. [1] Pirmohamed, M., Pharmacogenetics and pharmacogenomics. Br J Clin Pharmacol 52:4 (2001), 345–347.
2. [2] Ehmann, F., Caneva, L., Prasad, K., Paulmichl, M., Maliepaard, M., Llerena, A., et al. Pharmacogenomic information in drug labels: European Medicines Agency perspective. Pharmacogenomics J 15:3 (2015), 201–210.
3. [3] Gaedigk, A., Leeder, J.S., CYP2D6 and pharmacogenomics: where does future research need to focus? Part 1: technical aspects. Pharmacogenomics 15:4 (2014), 407–410.
4. [4] Hicks, J.K., Bishop, J.R., Sangkuhl, K., Muller, D.J., Ji, Y., Leckband, S.G., et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther 98:2 (2015), 127–134.
5. [5] Pirmohamed, M., Pharmacogenetics: past, present and future. Drug Discov Today 16:19–20 (2011), 852–861.
6. [6] Heiba, I.M., Elston, R.C., Klein, B.E., Klein, R., Sibling correlations and segregation analysis of age-related maculopathy: the Beaver Dam Eye Study. Genet Epidemiol 11:1 (1994), 51–67.
7. [7] Meyers, S.M., Greene, T., Gutman, F.A., A twin study of age-related macular degeneration. Am J Ophthalmol 120:6 (1995), 757–766.
8. [8] Klaver, C.C., Wolfs, R.C., Assink, J.J., van Duijn, C.M., Hofman, A., de Jong, P.T., Genetic risk of age-related maculopathy. Population-based familial aggregation study. Arch Ophthalmol 116:12 (1998), 1646–1651.
9. [9] Bradley, D.T., Zipfel, P.F., Hughes, A.E., Complement in age-related macular degeneration: a focus on function. Eye (Lond) 25:6 (2011), 683–693.
10. [10] Burns, D.K., Hughes, A.R., Power, A., Wang, S.J., Patterson, S.D., Designing pharmacogenomic studies to be fit for purpose. Pharmacogenomics 11:12 (2010), 1657–1667.
11. [11] Mallal, S., Nolan, D., Witt, C., Masel, G., Martin, A.M., Moore, C., et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359:9308 (2002), 727–732.
12. [12] Hetherington, S., Hughes, A.R., Mosteller, M., Shortino, D., Baker, K.L., Spreen, W., et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 359:9312 (2002), 1121–1122.
13. [13] Phillips, E.J., Sullivan, J.R., Knowles, S.R., Shear, N.H., Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir. AIDS 16:16 (2002), 2223–2225.
14. [14] Mallal, S., Phillips, E., Carosi, G., Molina, J.M., Workman, C., Tomazic, J., et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 358:6 (2008), 568–579.
15. [15] Chan, B.A., Hughes, B.G., Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Transl Lung Cancer Res 4:1 (2015), 36–54.
16. [16] Barlesi, F., Mazieres, J., Merlio, J.P., Debieuvre, D., Mosser, J., Lena, H., et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet 387:10026 (2016), 1415–1426.
17. [17] Lee, C., Usenko, D., Frampton, G.M., McMahon, C., Ali, S.M., Weiss, J., MET 14 deletion in sarcomatoid non-small-cell lung cancer detected by next-generation sequencing and successfully treated with a MET inhibitor. J Thorac Oncol 10:12 (2015), e113–e114.
18. [18] Gallant, J.N., Sheehan, J.H., Shaver, T.M., Bailey, M., Lipson, D., Chandramohan, R., et al. EGFR kinase domain duplication (EGFR-KDD) is a novel oncogenic driver in lung cancer that is clinically responsive to Afatinib. Cancer Discov 5:11 (2015), 1155–1163.
19. [19] Klempner, S.J., Bazhenova, L.A., Braiteh, F.S., Nikolinakos, P.G., Gowen, K., Cervantes, C.M., et al. Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI. Lung Cancer 89:3 (2015), 357–359.
20. [20] Baars, M.J., Henneman, L., Ten Kate, L.P., Deficiency of knowledge of genetics and genetic tests among general practitioners, gynecologists, and pediatricians: a global problem. Genet Med 7:9 (2005), 605–610.
21. [21] Johansen Taber, K.A., Dickinson, B.D., Pharmacogenomic knowledge gaps and educational resource needs among physicians in selected specialties. Pharmgenomics Pers Med 7 (2014), 145–162.
22. [22] Klitzman, R., Chung, W., Marder, K., Shanmugham, A., Chin, L.J., Stark, M., et al. Attitudes and practices among internists concerning genetic testing. J Genet Couns 22:1 (2013), 90–100.
23. [23] Perry, C.G., Maloney, K.A., Beitelshees, A.L., Jeng, L.J., Ambulos, N.P. Jr., Shuldiner, A.R., et al. Educational innovations in clinical pharmacogenomics. Clin Pharmacol Ther 99:6 (2016), 582–584.
24. [24] Vernez, S.L., Salari, K., Ormond, K.E., Lee, S.S., Personal genome testing in medical education: student experiences with genotyping in the classroom. Genome Med, 5(3), 2013, 24.
25. [25] Kuo, G.M., Lee, K.C., Ma, J.D., Implementation and outcomes of a live continuing education program on pharmacogenomics. Pharmacogenomics 14:8 (2013), 885–895.
26. [26] Kimmel, S.E., Warfarin pharmacogenomics: current best evidence. J Thromb Haemost 13:Suppl 1 (2015), S266–S271.
27. [27] Pirmohamed, M., Burnside, G., Eriksson, N., Jorgensen, A.L., Toh, C.H., Nicholson, T., et al. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med 369:24 (2013), 2294–2303.
28. [28] van der Baan, F.H., Klungel, O.H., Egberts, A.C., Leufkens, H.G., Grobbee, D.E., Roes, K.C., et al. Pharmacogenetics in randomized controlled trials: considerations for trial design. Pharmacogenomics 12:10 (2011), 1485–1492.
29. [29] Sorich, M.J., Rowland, A., Wiese, M.D., Pharmacogenomic substudies of randomized controlled trials: consideration of safety outcomes. Ther Adv Drug Saf 5:2 (2014), 62–66.
30. [30] Frueh, F.W., Back to the future: why randomized controlled trials cannot be the answer to pharmacogenomics and personalized medicine. Pharmacogenomics 10:7 (2009), 1077–1081.
31. [31] Evaluation of Genomic Applications in, P., Prevention Working, G., The EGAPP initiative: lessons learned. Genet Med 16:3 (2014), 217–224.
32. [32] McClain, M.R., Palomaki, G.E., Piper, M., Haddow, J.E., A rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding. Genet Med 10:2 (2008), 89–98.